Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia.
acute lymphoblastic leukemia
bispecific T-cell engager
bispecific antibody
blinatumomab
measurable residual disease
myelosuppression
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
09 Nov 2021
09 Nov 2021
Historique:
received:
27
09
2021
revised:
02
11
2021
accepted:
06
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Association of blinatumomab treatment with myelosuppression was examined in this study. Peripheral blood counts were assessed prior to, during, and after blinatumomab treatment in patients with relapsed/refractory Philadelphia chromosome-negative (Ph-) B-cell precursor (BCP) acute lymphoblastic leukemia (ALL;
Identifiants
pubmed: 34830762
pii: cancers13225607
doi: 10.3390/cancers13225607
pmc: PMC8616108
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Amgen Inc.
ID : Not applicable
Organisme : Astellas Pharma, Inc.
ID : Not applicable
Références
Biologics. 2020 Feb 14;14:23-34
pubmed: 32103893
Semin Oncol Nurs. 1992 May;8(2):113-23
pubmed: 1621002
Cancer Med J. 2020;3(1):40-48
pubmed: 32405629
Arch Dis Child. 1989 Sep;64(9):1231-4
pubmed: 2684039
JAMA. 2021 Mar 2;325(9):843-854
pubmed: 33651091
Immunology. 2021 Jan;162(1):30-43
pubmed: 32935333
J Clin Oncol. 1998 Jun;16(6):2065-9
pubmed: 9626205
J Clin Invest. 2021 Apr 1;131(7):
pubmed: 33571162
Blood. 2018 Apr 5;131(14):1522-1531
pubmed: 29358182
Med (N Y). 2021 Mar 12;2(3):281-295.e4
pubmed: 33589885
Pediatr Blood Cancer. 2021 Feb;68(2):e28763
pubmed: 33047887
Exp Hematol Oncol. 2017 May 18;6:14
pubmed: 28533941
Cancer. 2008 Oct 15;113(8):2097-101
pubmed: 18720356
Cancer. 2013 Aug 1;119(15):2728-36
pubmed: 23633004
Clin Infect Dis. 1994 Jan;18(1):25-31
pubmed: 8054434
Cancer Biol Med. 2013 Jun;10(2):92-8
pubmed: 23882424
N Engl J Med. 2017 Mar 2;376(9):836-847
pubmed: 28249141
Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):e801-e809
pubmed: 34376375
Bone Marrow Transplant. 2018 Apr;53(4):449-456
pubmed: 29330398
Blood. 2020 Aug 20;136(8):925-935
pubmed: 32582924
Acta Haematol. 2021;144(2):132-145
pubmed: 32392559
PLoS One. 2021 Jan 25;16(1):e0245532
pubmed: 33493185
Leuk Res. 2020 Jan;88:106283
pubmed: 31790983
Blood. 2020 Sep 3;136(10):1134-1143
pubmed: 32688395
Cancer. 2004 Jan 15;100(2):228-37
pubmed: 14716755
Blood Cancer J. 2020 Jul 24;10(7):77
pubmed: 32709851
JAMA. 2021 Mar 2;325(9):833-842
pubmed: 33651090
N Engl J Med. 2016 Aug 25;375(8):740-53
pubmed: 27292104
Science. 2008 Aug 15;321(5891):974-7
pubmed: 18703743
Exp Hematol Oncol. 2012 Nov 29;1(1):36
pubmed: 23210908
Pediatr Blood Cancer. 2018 Apr;65(4):
pubmed: 29230962
Infection. 2014 Feb;42(1):5-13
pubmed: 23975584
Cureus. 2021 May 26;13(5):e15256
pubmed: 34188994
Clin Adv Hematol Oncol. 2012 Dec;10(12):825-6
pubmed: 23271355
Int J Cancer. 2005 May 20;115(1):98-104
pubmed: 15688411
J Clin Oncol. 2017 Jun 1;35(16):1795-1802
pubmed: 28355115
Blood Cancer J. 2014 Sep 05;4:244
pubmed: 25192414
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Immunity. 2021 Feb 9;54(2):205-210
pubmed: 33513337
Blood. 2008 Aug 15;112(4):1048-55
pubmed: 18495958
Pharmacogenomics J. 2018 Apr;18(2):270-274
pubmed: 28534526
Blood. 2012 Jun 28;119(26):6226-33
pubmed: 22592608
Haematologica. 2019 Jun;104(6):e244-e247
pubmed: 30765470
Pediatr Hematol Oncol. 2008 Jun;25(5):385-92
pubmed: 18569840